Type of non Hodgkin's lymphoma-Mantle cell lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Mantle cell lymphoma Posts on Medivizor

Evaluating allogeneic stem cell transplantation for patients with mantle cell lymphoma

Evaluating allogeneic stem cell transplantation for patients with mantle cell lymphoma

Posted by on May 30, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of an allogeneic stem cell transplant (alloSCT) for patients with mantle cell lymphoma (MCL). The authors concluded that this treatment was effective for high-risk patients. Some background MCL is an aggressive type of non-Hodgkin lymphoma (NHL). Chemoimmunotherapy is the typical first-line...

Read More

Evaluating pirtobrutinib for the treatment on B cell leukemia/lymphoma

Evaluating pirtobrutinib for the treatment on B cell leukemia/lymphoma

Posted by on Apr 30, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study tested the safety and effectiveness of pirtobrutinib (LOXO-305) in the treatment of patients with B cell leukemia/lymphoma. The authors found that pirtobrutinib was safe and had promising effectiveness in these patients. Some background B cells are a type of cell of the immune system. Some lymphomas and leukemias such as...

Read More

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Posted by on Jan 17, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of GDP (gemcitabine, dexamethasone, and cisplatin) and ICE (ifosfamide, carboplatin, and etoposide) regimens as salvage therapy in patients with relapsed/refractory aggressive lymphoma. The data showed that both the GDP and ICE regimens are suitable options for relapsed/refractory...

Read More

Testing the safety and effectiveness of loncastuximab tesirine for the treatment of relapsed/refractory B-cell non-hodgkin lymphoma

Testing the safety and effectiveness of loncastuximab tesirine for the treatment of relapsed/refractory B-cell non-hodgkin lymphoma

Posted by on Dec 26, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to evaluate the safety and effectiveness of loncastuximab tesirine (LoT; Lonca) for the treatment of patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The study found that LoT was safe and had promising activity in these patients.  Some background B-NHL is a type of...

Read More

Evaluating bendamustine with ofatumumab, carboplatin and etoposide for relapsed/refractory aggressive non-Hodgkin lymphoma

Evaluating bendamustine with ofatumumab, carboplatin and etoposide for relapsed/refractory aggressive non-Hodgkin lymphoma

Posted by on Dec 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the combination of bendamustine (Treanda), ofatumumab (Arzerra), carboplatin (Paraplatin), and etoposide (Etopophos) in patients with relapsed/refractory aggressive non-Hodgkin lymphoma (NHL).   This study concluded that this combination was safe and effective in these...

Read More

Second stem cell transplant using reduced intensity conditioning for leukemia or lymphoma

Second stem cell transplant using reduced intensity conditioning for leukemia or lymphoma

Posted by on Oct 25, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the outcomes of a second hematopoietic stem cell transplant (HSCT) after reduced-intensity conditioning (RIC) for patients with leukemia or lymphoma.   This study concluded that this treatment path is feasible and a good treatment alternative for these patients.   Some background Allogenic...

Read More

Looking for participants to test an experimental immunotherapy for relapsed non-Hodgkin lymphoma

Looking for participants to test an experimental immunotherapy for relapsed non-Hodgkin lymphoma

Posted by on Oct 11, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will evaluate the antibody therapy odronextamab for patients with relapsed B-cell non-Hodgkin lymphoma (NHL). The primary outcomes will be how many patients respond to treatment, and how many have a complete response (cancer no longer detectable).  The details For B-cell NHL which has relapsed (returned) after...

Read More

Treating patients with B-cell non-Hodgkin lymphoma with immunoglobulin replacement therapy after rituximab treatment

Treating patients with B-cell non-Hodgkin lymphoma with immunoglobulin replacement therapy after rituximab treatment

Posted by on Sep 6, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the outcomes of immunoglobulin replacement (IgR) therapy in patients with B-cell non-Hodgkin lymphoma (B-NHL) and immunodeficiency, who were previously treated with rituximab (Rituxan). The authors found that IgR was safe and effective to increase serum immunoglobulins in such patients. Some background B-NHL happens...

Read More

Impact of graft cryopreservation on allogeneic hematopoietic stem cell transplant outcomes using post-transplant cyclophosphamide

Impact of graft cryopreservation on allogeneic hematopoietic stem cell transplant outcomes using post-transplant cyclophosphamide

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to compare outcomes of allogeneic hematopoietic stem cell transplant (alloHSCT) using cryopreserved (frozen) and fresh grafts in patients with blood cancers who received post-transplant cyclophosphamide (Cytoxan). This study concluded that cryopreservation (CP) does not affect the outcomes of HSCT in these patients....

Read More

Can immunotherapy increase the effectiveness of following treatments for patients with relapsed or unresponsive non-Hodgkin lymphoma?

Can immunotherapy increase the effectiveness of following treatments for patients with relapsed or unresponsive non-Hodgkin lymphoma?

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined if pre-treatment with immunotherapy could improve the effectiveness of following treatment for patients with hard-to-treat non-Hodgkin lymphoma (NHL). The results indicated that immunotherapies increased the effectiveness of other treatments such as chemotherapy for some patients. Some background While...

Read More

How effective and safe is biological therapy rituximab for children with non-Hodgkin lymphoma?

How effective and safe is biological therapy rituximab for children with non-Hodgkin lymphoma?

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined if adding biological therapy rituximab (Rituxan) to chemotherapy improved treatment results for children with non-Hodgkin lymphoma. The results showed that rituximab improved patients’ chances of survival but also caused more side effects. Some background Treatment results for children with NHL have...

Read More